Huahai Pharmaceutical announced that the company recently received the Drug Registration Certificate for Ferrous Succinate Tablets approved and issued by the National Medical Products Administration. The drug is used for the prevention and treatment of iron deficiency anemia. Approval for production as a Category 3 chemical drug is deemed equivalent to passing the consistency evaluation. In 2025, the domestic market sales of this drug amounted to approximately 408 million yuan, and the company's R&D investment was about 5.15 million yuan. This approval will further enrich the company's product line and enhance market competitiveness.
Zhejiang Huahai Pharmaceutical Co LtdObtained drug registration certificate for Ferrous Succinate Tablets, a new product approval.